 ADENOCARCINOMA OF LUNG, SOMATIC
|
ADVANCED SLEEP PHASE SYNDROME, FAMILIAL, 2
|
AMYOTROPHIC LATERAL SCLEROSIS 19
|
AORTIC ANEURYSM, FAMILIAL THORACIC 7
|
BLADDER CANCER, SOMATIC, INCLUDED
|
BRACHYDACTYLY, TYPE A2
|
BREAST CANCER, SUSCEPTIBILITY TO
|
CAMPTODACTYLY, TALL STATURE, AND HEARING LOSS SYNDROME
|
CARDIOFACIOCUTANEOUS SYNDROME 1
|
CARDIOFACIOCUTANEOUS SYNDROME 3
|
CARDIOFACIOCUTANEOUS SYNDROME 4
|
CATARACT 6, AGE-RELATED CORTICAL
|
CEREBRAL INFARCTION, SUSCEPTIBILITY TO
|
CHRONIC MYELOID LEUKEMIA, RESISTANT TO IMATINIB
|
COLON CANCER, SOMATIC
|
COLORECTAL CANCER, SOMATIC
|
COLORECTAL CANCER, SOMATIC, INCLUDED;;
|
CROUZON SYNDROME
|
DEFICIENCY
|
DIABETES MELLITUS, INSULIN-RESISTANT, WITH ACANTHOSIS NIGRICANS
|
DIABETES MELLITUS, NONINSULIN-DEPENDENT
|
DIABETES MELLITUS, TYPE II
|
ENDOCRINE-CEREBROOSTEODYSPLASIA
|
ENDOCRINE-CEREBROOSTEODYSPLASIA (ECO)
|
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 2
|
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 2 (EIEE2)
|
FG SYNDROME 4
|
FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
|
GERM CELL TUMOR, SOMATIC
|
GLYCOGEN STORAGE DISEASE IXC
|
HARTSFIELD SYNDROME
|
HEMANGIOMA, CAPILLARY INFANTILE, SOMATIC
|
HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC
|
HIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1
|
HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 5
|
HYPOCHONDROPLASIA
|
HYPOGONADOTROPIC HYPOGONADISM 2 WITH ANOSMIA
|
HYPOGONADOTROPIC HYPOGONADISM 2 WITH ANOSMIA, SUSCEPTIBILITY TO
|
HYPOGONADOTROPIC HYPOGONADISM 2 WITH OR WITHOUT ANOSMIA, SUSCEPTIBILITY
|
HYPOGONADOTROPIC HYPOGONADISM 2 WITHOUT ANOSMIA
|
HYPOGONADOTROPIC HYPOGONADISM 2 WITHOUT ANOSMIA, SUSCEPTIBILITY TO
|
INSENSITIVITY TO PAIN, CONGENITAL, WITH ANHIDROSIS
|
INSULIN RESISTANCE
|
INSULIN RESISTANCE, INCLUDED
|
IRAK4 DEFICIENCY
|
LADD SYNDROME
|
LEUKEMIA, ACUTE MYELOID
|
LEUKEMIA, PHILADELPHIA CHROMOSOME-POSITIVE, RESISTANT TO IMATINIB
|
LOEYS-DIETZ SYNDROME, TYPE 1A
|
LOEYS-DIETZ SYNDROME, TYPE 2A
|
LOEYS-DIETZ SYNDROME, TYPE 2A, INCLUDED
|
LYMPHEDEMA, HEREDITARY, I
|
LYMPHEDEMA, HEREDITARY, IA
|
LYMPHOMA, NON-HODGKIN, SOMATIC
|
LYMPHOPROLIFERATIVE SYNDROME 1
|
MALFORMATIONS
|
MAST CELL DISEASE, SYSTEMIC
|
MAST CELL LEUKEMIA
|
MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC DISORDER, INCLUDED;;
|
MASTOCYTOSIS, ADULT SPORADIC, INCLUDE
|
MASTOCYTOSIS, SPORADIC, CHILDHOOD-ONSET
|
MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME
|
MELANOMA, MALIGNANT, SOMATIC
|
MENTAL RETARDATION AND MICROCEPHALY WITH PONTINE AND CEREBELLAR HYPOPLASIA
|
MENTAL RETARDATION, X-LINKED 30
|
MENTAL RETARDATION, X-LINKED, WITH NYSTAGMUS
|
MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIA
|
MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB
|
MULTIPLE MYELOMA, SOMATIC, INCLUDED;;
|
MULTIPLE SELF-HEALING SQUAMOUS EPITHELIOMA, SUSCEPTIBILITY TO
|
MYASTHENIC SYNDROME, CONGENITAL, ASSOCIATED WITH ACETYLCHOLINE RECEPTOR
|
NEPHRONOPHTHISIS 9 (NPHP9)
|
NEUROBLASTOMA, SUSCEPTIBILITY TO, 3
|
NEUROPATHY, HEREDITARY SENSORY, TYPE II
|
NOONAN SYNDROME 7
|
OBESITY, HYPERPHAGIA, AND DEVELOPMENTAL DELAY
|
OGUCHI DISEASE 2
|
PARKINSON DISEASE 8, AUTOSOMAL DOMINANT
|
PEUTZ-JEGHERS SYNDROME
|
PFEIFFER SYNDROME
|
PHEOCHROMOCYTOMA, INCLUDED
|
PHEOCHROMOCYTOMA, SOMATIC, IN
|
PIEBALDISM
|
PIEBALDISM WITH SENSORINEURAL DEAFNESS
|
PROSTATE CANCER, PROGRESSION AND METASTASIS OF
|
RENAL AGENESIS
|
RENAL CELL CARCINOMA, PAPILLARY, 1
|
RENAL CELL CARCINOMA, PAPILLARY, 1, SOMATIC
|
RETINITIS PIGMENTOSA 38
|
RETINITIS PIGMENTOSA 62
|
RETINITIS PIGMENTOSA 62 (RP62)
|
SADDAN DYSPLASIA
|
SCAPHOCEPHALY, MAXILLARY RETRUSION, AND MENTAL RETARDATION, INCLUDED
|
SHORT RIB-POLYDACTYLY SYNDROME 2A (SRPS2A)
|
SHORT RIB-POLYDACTYLY SYNDROME, TYPE IIA
|
SPERMATOCYTIC SEMINOMA, SOMATIC, INCLUDED
|
SPERMATOGENIC FAILURE 5
|
SPINOCEREBELLAR ATAXIA 14
|
SPONDYLOMETAEPIPHYSEAL DYSPLASIA, SHORT LIMB-HAND TYPE
|
T-CELL IMMUNODEFICIENCY, RECURRENT INFECTIONS, AUTOIMMUNITY, AND CARDIAC
|
TESTICULAR TUMOR, SOMATIC
|
THANATOPHORIC DYSPLASIA, TYPE I
|
THANATOPHORIC DYSPLASIA, TYPE I, INCLUDED
|
THANATOPHORIC DYSPLASIA, TYPE II
|
THYROID CARCINOMA, FAMILIAL MEDULLARY
|
THYROID CARCINOMA, FAMILIAL MEDULLARY, INCLUDED
|
THYROID CARCINOMA, FOLLICULAR, SOMATIC, INCLUDED
|
THYROID CARCINOMA, PAPILLARY, SOMATIC, INCLUDED;;|
|
THYROID CARCINOMA, SPORADIC MEDULLARY, INCLUDED;;
|
TO
|
VENOUS MALFORMATIONS, MULTIPLE CUTANEOUS AND MUCOSAL
|
Catalytic domain of the Serine/Threonine Kinase, Fungal Cyclin-Dependent protein Kinase Bypass UAS Requirement 1 and similar proteins. Serine/Threonine Kinases (STKs), Bypass UAS Requirement 1 (BUR1) subfamily, catalytic (c) domain. STKs catalyze the transfer of the gamma-phosphoryl group from ATP to serine/threonine residues on protein substrates. The BUR1 subfamily is part of a larger superfamily that includes the catalytic domains of other protein STKs, protein tyrosine kinases, RIO kinases, aminoglycoside phosphotransferase, choline kinase, and phosphoinositide 3-kinase. CDKs belong to a large family of STKs that are regulated by their cognate cyclins. Together, they are involved in the control of cell-cycle progression, transcription, and neuronal function. BUR1, also called SGV1, is a yeast Cyclin-Dependent protein Kinase (CDK) that is functionally equivalent to mammalian CDK9. It associates with the cyclin BUR2. BUR genes were orginally identified in a genetic screen as factors involved in general transcription. The BUR1/BUR2 complex phosphorylates the C-terminal domain of RNA polymerase II. In addition, this complex regulates histone modification by phosporylating Rad6 and mediating the association of the Paf1 complex with chromatin.
No pairwise interactions are available for this conserved domain.
